Our Products

See our range of cfDNA products below.


Ensuring successful cfDNA analysis is our focus

Every sample is precious and to get the most out of your sample when evaluating cfDNA it is really critical to have processed your samples correctly from blood collection through to extracted cfDNA. Learn more about our Cell3 Preserver blood tube and Cell3 Xtract kit below.

Prenatal Healthcare

Non-invasive prenatal testing requires sensitive, reproducible and easy to use products.

Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.


Efficient workflow enables confident calling of all ctDNA mutations

Nonacus are working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.

Who we are

Designed by scientists, for Scientists

We are formed of a committed group of biotechnology professionals with a combined 35 years experience in genomic healthcare. We understand the pressure on laboratories to deliver progress and our products are designed to get you there. Between us, we’ve got global experience of genomic healthcare from the NHS in the UK through to an international genome project.

Designed by scientists
True Innovation

What we stand for

True Innovation That Benefits Patients

We translate research into routine diagnostic tools that directly benefit patients and scientists. Our non-invasive cell free DNA solutions improve diagnostic accuracy as well as the patient’s experience. Our research & development team are constantly developing, validating and testing new cfDNA products.

Built For Labs That Do


We supply Universities with our cfDNA products to help them improve their understanding and research in non-invasive healthcare.


Leading hospitals have adopted our products to help improve patient care through the innovative use of cfDNA technology allowing for non-invasive diagnostics.

Research Facilities

We partner with many leading laboratories to constantly innovate and push our products further.

Research Facilities

Read Our Latest Insights

Birmingham University and Nonacus partner to develop urine test for bladder cancer

May 17, 2022

Last July we announced that Nonacus and the University of Birmingham had partnered to develop a non-invasive test for bladder cancer. The test uses highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated by Dr Rik Bryan and Dr Douglas Ward from the University’s Bladder Cancer Research Centre, to diagnose the disease from urine samples. Now, less that a year later, the first results are in.

Read More
liquid biopsy mrd detection

Liquid Biopsy: The Future Of Minimal Residual Disease Detection

March 24, 2022

The assessment of post-treatment minimal residual disease remains challenging clinically as current gold-standard methods do not exhibit sufficient sensitivity and specificity’. This wastes precious time where using a more sensitive and informative method such as liquid biopsy may allow the clinician to act earlier and stratify treatment more appropriately to enhance patient outcomes.

Read More
Detecting multiple respiratory viruses

Detecting multiple respiratory viruses with a single qRT-PCR assay

March 16, 2022

As some of the symptoms of COVID-19 overlap with flu and respiratory syncytial virus (RSV), a negative COVID test result doesn’t always give the full picture of infection. Testing for multiple respiratory viruses in one simple qRT-PCR test could be the answer.

Read More

Upcoming Events

EACR Cancer Genomics

5-7 July 2022

John Henry Brookes Building

Oxford, UK

ACGS Summer Meeting

11-12 July 2022

The International Conference Centre

Birmingham, UK

European Congress of Pathology

3-7 September 2022

Congress Centre, Basel

Basel, Switzerland

Are you ready to innovate your cfDNA capability?

Contact us for a quote.